AI Diagnostic Pioneer IDx Secures $33M Series A Funding to Accelerate FDA-Cleared Platform Development and Commercialization

VCBeat (WeChat Official Account: vcbeat) learned that on September 26, IDx, an artificial intelligence startup based in Iowa, USA, announced it had secured $33 million in funding from investors including 8VC and Optum Ventures. The proceeds from this round will be used to accelerate the deployment of IDx’s AI products and advance its commercialization efforts; a portion of the funds will also be allocated to the development of new AI systems.

This marks IDx’s second fundraising round this year. On May 30, IDx secured $7.97 million in seed funding. In just four months, the company has raised an additional $33 million in Series A financing.

IDx’s AI software system, IDx-DR, received FDA approval in April. This product is designed for the autonomous detection of diabetic retinopathy. According to the FDA, this decision marks the first artificial intelligence-based diagnostic system authorized by the U.S. Food and Drug Administration for commercialization, enabling it to provide screening results to patients without the need for interpretation by a clinician.

When granting certification, the FDA noted that IDx’s collaborative model with physicians for diabetic retinopathy screening was highly effective; it sought to partner with clinicians to address challenges, rather than following Google’s path of continually competing against them.

The entire approval process took two years, with a significant amount of time devoted to communications with the FDA regarding how to evaluate the system and ensure its accuracy and safety.

According to the survey results, the IDx AI system achieved a sensitivity of 87%, a specificity of 90%, and an imageability rate of 96%. Under the same sensitivity testing criteria, ophthalmologists had an average accuracy of 73%, with the lowest individual accuracy being only 33%.

“In the United States alone, 30 million patients require screening for diabetic retinopathy each year. This represents a vast market, yet we lack sufficient physician resources to meet the demand. The launch of IDx-DR offers an effective solution to this challenge, as our product can provide recommendations to patients without the need for physician assistance,” said an IDx-DR executive at the press conference.

“The healthcare sector needs to accelerate the research, development, and regulatory approval of artificial intelligence to reduce medical costs and improve efficiency,” said Sarah London, Senior Executive at Optum Ventures. Its partner company, Optum, is a leading healthcare information services provider and a subsidiary of UnitedHealth. “We believe that IDx will better serve patients by helping to prevent diabetic retinopathy and avoiding vision loss caused by this condition. This is why we are helping IDx build a bridge between physicians and patients.”

“Several of the world’s largest companies are attempting to develop artificial intelligence in the healthcare sector, but IDx is leading the way in practical implementation,” said Drew Oetting, Founding Partner at 8VC. “The company has leveraged its ophthalmology expertise to develop a specialized AI product. This innovative, biomarker-based approach distinguishes IDx from mere hype-driven competitors, making it the first company to introduce AI technology into the medical field and receive FDA clearance.”

Today, IDx is developing other AI-based diagnostic systems that will be used to detect macular degeneration, glaucoma, Alzheimer's disease, cardiovascular diseases, and even help patients prevent strokes. With the funding from this round, IDx’s pace of commercialization is bound to accelerate.